Solabegron: a potential future addition to the β-3 adrenoceptor agonist armamentarium for the management of overactive bladder

Bibliography

• Abrams P, Cardozo L, Magnus F, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neuro Urol 2002;21:167-78
   PubMed Web of Science ®Google Scholar
• Irwin DE, Abrams P, Milsom I, et al. Understanding the elements of overactive bladder: questions rased by the EPIC study. BJU Int 2008;11:1381-7
   Google Scholar
• Stewart WF, Van Rooven JB, Cundigg GW, et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20(6):327-36
   PubMed Web of Science ®Google Scholar
• Coyne K, Wein A, Nicholson S, et al. Economic burden of urgency urinary incontinence in the United State: a systematic review. J Manag Care Pharm 2014;20(2):130-40
   PubMed Web of Science ®Google Scholar
• Gormley EA, Lightner DJ, Burgio KL, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. J Urol 2012;188(6 Suppl):2455-63
   PubMed Web of Science ®Google Scholar
• Lucas MG, Bosch RJ, Cruz F, et al. EAU guidelines on urinary incontinence. http://www.uroweb.org/guidelines/online-guidelines Last accessed 22 November 2014]
   Google Scholar
• Mirabegron for treating symptoms of overactive bladder. UK NICE: national Institute for Health and Care Excellence. 2014. Available from: https://www.NICE.org.uk [Last accessed 22 November 2014]
   Google Scholar
• Madhuvrata P, Cody JD, Ellis G, et al. Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2012;1:CD005429
   PubMedGoogle Scholar
• Buser N, Ivic S, Kessler TM, et al. Efficacy and adverse events of antimuscarinics for treating overactive bladder: network meta-analyses. Eur Urol 2012;62:1040-60
   PubMed Web of Science ®Google Scholar
• Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005;48:5-26
   PubMed Web of Science ®Google Scholar
• Chapple CR, Khullar V, Gabriel Z, et al. The effects of antimuscarinic treatments in overactive bladder: an update of a systematic review and meta-analysis. Eur Urol 2008;54:543-62
   PubMed Web of Science ®Google Scholar
• Novara G, Galfano A, Secco S, et al. A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008;54:740-64
   PubMed Web of Science ®Google Scholar
• Wagg A, Compion G, Fahey A, Siddiqui E. Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int 2012;110:1767-74
   PubMed Web of Science ®Google Scholar
• Sink KM, Thomas JIII, Xu H, et al. Use of bladder anticholinergics and cholinesterase inhibitors: long-term cognitive and functional outcome. J Amer Geriatr Soc 2008;56(5):847-53
   PubMed Web of Science ®Google Scholar
• Maman K, Aballea S, Nazir J, et al. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Eur Urol 2014;65:755-65
   PubMed Web of Science ®Google Scholar
• Campbell-Walsh Urology. 10th edition. W.B. Saunders; Philadelphia: 2012
   Google Scholar
• Andersson KE, Arner A. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004;3):935-86
   PubMed Web of Science ®Google Scholar
• DeLaet K, DeWachter S, Wyndaele JJ. Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 2006;25(2):156-61
   PubMed Web of Science ®Google Scholar
• Iijima K, DeWachter S, Wyndaele JJ. Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 2007;52(3):842-7
   PubMed Web of Science ®Google Scholar
• Michel MC, Vrydag W. Alpha 1-, alpha 2- and beta- adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 2007;147:S88-119
   Web of Science ®Google Scholar
• Otsuka A, Shinbo H, Matsumoto R, et al. Expression and functional role of beta-adrenoceptors in the human urinary bladder epithelium. Naunyn Schmiedebergs Arch Pharmacol 2008;377:473-81
   PubMed Web of Science ®Google Scholar
• Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol 2003;170:649-53
   PubMed Web of Science ®Google Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Functional and molecular biological evidence for a possible B3-adrenoceptor in the human detrusor muscle. Br J Pharmacol 1999;126:819-25
   PubMed Web of Science ®Google Scholar
• Morita T, Iizuka H, Iwata T, et al. Function and distribution of beta 3-adrenoceptors in rat, rabbit and human urinary bladder and external urethral sphincter. J Smooth Muscle Res 2000;36:21-32
   PubMedGoogle Scholar
• Biers S M, Reynard JM, Brading AF. The effects of a new selective beta3-adrenoceptor agonist (GW427353) on spontaneous activity and detrusor relaxation in human bladder. BJU Int 2006;98(6):1310-14
   PubMed Web of Science ®Google Scholar
• Fujimara T, Tamura K, Tsutsumi T, et al. Expression and possible functional role of the beta 3-adrenergic receptors in human and rat detrusor muscle. J Urol 1999;161:680-5
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Adachi-Akahanse S, Nagano T. Involvement of BK (Ca) channels in the relaxation of detrusor muscle via beta-adrenoceptors. Eur J Pharmacol 2000;404:231-8
   PubMed Web of Science ®Google Scholar
• Kullman FA, Downs TR, Artim DE, et al. Urothelial beta-3 adrenergic receptors in the rat bladder. Neurourol Urodyn 2011;30:144-50
   PubMed Web of Science ®Google Scholar
• Masunaga K, Chapple CR, McKay NG, et al. The beta 3-adrenoceptor mediates the inhibitory effects of b-adrenoceptor agonists via the urothelium in pig bladder dome. Neurourol Urodyn 2010;29:1320-5
   PubMed Web of Science ®Google Scholar
• Propping S, Wuest M, Eichhorn B, et al. Role of urothelium on B3-adrenoceptor mediated relaxation in human detrusor muscle. Neurourol Urodyn 2009;28:870-1
   Web of Science ®Google Scholar
• Woods M, Carson N, Norton NW, et al. Efficacy of the beta 3-adrenergic receptor agonist CL-316243 on experimental bladder hyperreflexia and detrusor instability in the rat. J Urol 2001;166:1142-7
   PubMed Web of Science ®Google Scholar
• Kaidoh K, Igawa Y, Takeda H, et al. Effects of selective beta 2 and beta 3-adrenoceptor agonists on detrusor hyperreflexia in conscious cerebral infarcted rats. J Urol 2002;168:1247-52
   PubMed Web of Science ®Google Scholar
• Igawa Y, Yamazaki Y, Takeda H, et al. Relaxant effects of isoproterenol and selective beta 3 AR agonists on normal, low compliant and hyperreflexic human bladders. J Urol 2001;165:240-4
   PubMed Web of Science ®Google Scholar
• Tyagi P, Thomas CA, Yoshimura N, Chancellor MB. Investigations into the presence of functional beta1, beta2 and beta3-adrenoceptors in urothelium and detrusor of human bladder. Int Braz J Urol 2009;35:76-83
   PubMed Web of Science ®Google Scholar
• Ursino MG, Vasina V, Raschi E, et al. The beta3- adrenoceptor as a therapeutic target: current perspectives. Pharmacol Res 2009;59(4):221-34
   PubMed Web of Science ®Google Scholar
• Grudell AB, Camilleri M, Jensen KL, et al. Dose-response effect of a beta 3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health. Amer J Physiol Gastrointest Liver Physiol 2008;294(5):G1114-19
   PubMed Web of Science ®Google Scholar
• Kelleher DL, Hicks KJ, Cox DS, et al. Randomized, double-blind, placebo (PLA)-controlled, crossover study to evaluate efficacy and safety of the beta 3-adrenergic receptor agonist solabegron (SOL) in patients with irritable bowel syndrome (IBS). Neurogastroenterol Motil 2008;20(suppl 2):131
   Google Scholar
• Cellek S, Thangiah R, Bassil AK, et al. Demonstration of functional neuronal beta3-adrenoceptors within the enteric nervous system. Gastroenterology 2007;133(1):175-83
   PubMed Web of Science ®Google Scholar
• Schemann M, Hafsi N, Michel K, et al. The beta3-adrenoceptor agonist GW427353 (solabegron) decreases excitability of human enteric neurons via release of somatostatin. Gastroenterology 2010;138(1):266-70
   PubMed Web of Science ®Google Scholar
• Michel MC, Harding SE, Bond RA. Are there functional B3-adrenoceptors in the human heart? Br J Pharmacol 2011;162:817-22
   PubMed Web of Science ®Google Scholar
• Gauthier C, Rozec B, Manoury B, et al. Beta -3 adrenoceptors as new therapeutic targets for cardiovascular pathologies. Curr Heart Fail Rep 2011;8(3):184-92
   PubMedGoogle Scholar
• Astellas Pharma US: Highlights of Prescribing Information. Available from: http://www.us.astellas.com/docs/mybetriq-full-pi.pdf
   Google Scholar
• Uehling DE, Shearer BG, Donaldson KH, et al. Biarylaniline phenethanolamines as potent and selective beta3 adrenergic receptor agonists. J Med Chem 2006;49:2758-71
   PubMed Web of Science ®Google Scholar
• Igawa Y, Michel MC. Pharmacological profile of beta3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn-Schmiedeberg’s Arch Pharmacol 2013;386(3):177-83
   Google Scholar
• Hicks A, McCafferty GP, Riedel E, et al. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog. J Pharmacol Exp Ther 2007;323(1):202-9
   PubMed Web of Science ®Google Scholar
• Ohlstein EH, von Keitz A, Michel MC. A multicenter, double-blind, randomized, placebo-controlled trial of the beta3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 2013;62(5):834-40
   Web of Science ®Google Scholar
• Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomized, double-blind, dose-ranging, Phase 2 study (Symphony). Eur Urol 2014. [Epub ahead of print]
   Google Scholar